AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...
EMHY iShares J.P. Morgan EM High Yield Bond ETF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback